AZ claims FDA okay for Brilinta in coronary artery disease patientsAstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first Share XAZ claims FDA okay for Brilinta in coronary artery disease patientshttps://pharmaphorum.com/news/az-claims-fda-okay-for-brilinta-in-coronary-artery-disease-patients/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
AstraZeneca on expanding its diabetes research franchiseAstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases. Richard Staines spoke Share XAstraZeneca on expanding its diabetes research franchisehttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/astrazeneca-takes-on-cvrm/
Amarin hit hard as generics loom for fish oil drug VascepaGeneric drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that Share XAmarin hit hard as generics loom for fish oil drug Vascepahttps://pharmaphorum.com/news/amarin-hit-hard-as-generics-loom-for-fish-oil-drug-vascepa/
Novartis plots cardio trial in UK as London HQ opensNovartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a Share XNovartis plots cardio trial in UK as London HQ openshttps://pharmaphorum.com/news/novartis-plots-cardio-trial-in-uk-as-london-hq-opens/
German court blocks Sanofi’s cholesterol drug after Amgen lawsuitAmgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a Share XGerman court blocks Sanofi’s cholesterol drug after Amgen lawsuithttps://pharmaphorum.com/news/german-court-blocks-sanofis-cholesterol-drug-after-amgen-lawsuit/
Amarin’s Vascepa gets priority review for cardiovascular label expansionAmarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results Share XAmarin’s Vascepa gets priority review for cardiovascular label expansionhttps://pharmaphorum.com/news/amarins-vascepa-gets-priority-review-for-cardiovascular-label-expansion/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Novartis licenses lipoprotein-lowering CVD drugExcited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment Share XNovartis licenses lipoprotein-lowering CVD drughttps://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/
